Pemmaraju Naveen, Kantarjian Hagop, Kadia Tapan, Cortes Jorge, Borthakur Gautam, Newberry Kate, Garcia-Manero Guillermo, Ravandi Farhad, Jabbour Elias, Dellasala Sara, Pierce Sherry, Verstovsek Srdan
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX.
Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX.
Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):171-6. doi: 10.1016/j.clml.2014.08.003. Epub 2014 Sep 17.
Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for the treatment of myelofibrosis.
We conducted a single-center phase I/II clinical study testing 3 dose levels (50 mg b.i.d. [n = 4], 100 mg b.i.d. [n = 5], and 200 mg b.i.d. [n = 18]). We enrolled 27 patients older than 14 years with relapsed or refractory acute myeloid leukemia (n = 26) or acute lymphoid leukemia (n = 1).
The median age was 66 (range, 25-88) years. Thirteen patients were evaluable for dose-limiting toxicities. The most common Grade 3 or 4 nonhematologic event was infection (n = 26 events; most frequently pneumonia; 15 of 26; 58%). One patient with multiple relapses after 7 lines of therapy had a CRp at a ruxolitinib dose of 200 mg b.i.d.
In this cohort of heavily pretreated patients with relapsed or refractory acute leukemias, ruxolitinib was overall reasonably well tolerated, with 1 patient achieving CRp.
芦可替尼是一种强效且特异性的JAK1/JAK2抑制剂，最近被批准用于治疗骨髓纤维化。
我们开展了一项单中心I/II期临床研究，测试了3个剂量水平（50毫克，每日两次[n = 4]；100毫克，每日两次[n = 5]；200毫克，每日两次[n = 18]）。我们纳入了27例年龄超过14岁、复发或难治性急性髓系白血病（n = 26）或急性淋巴细胞白血病（n = 1）的患者。
中位年龄为66岁（范围25 - 88岁）。13例患者可评估剂量限制性毒性。最常见的3级或4级非血液学事件是感染（n = 26起事件；最常见的是肺炎；26例中有15例；58%）。1例经过7线治疗后多次复发的患者在芦可替尼剂量为200毫克，每日两次时达到部分缓解（CRp）。
在这个经过大量预处理的复发或难治性急性白血病患者队列中，芦可替尼总体耐受性较好，有1例患者达到部分缓解（CRp）。
